Catabasis Pharmaceuticals

General Information

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Our initial focus is on treatments for rare diseases, such as Duchenne muscular dystrophy, or DMD.

Employees: 34
Founded: 2008
Contact Information
Address One Kendall Square Bldg. 1400E, Suite B14202, Cambridge, MA 02139, US
Phone Number (617) 349-1971
Web Address
View Prospectus: Catabasis Pharmaceuticals
Financial Information
Market Cap $174.6mil
Revenues $0.0 mil (last 12 months)
Net Income $-23.9 mil (last 12 months)
IPO Profile
Symbol CATB
Exchange NASDAQ
Shares (millions): 5.0
Price range $12.00 - $12.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Citigroup/ Cowen and Company
CO-Managers Oppenheimer/Wedbush PacGrow
Expected To Trade: 6/25/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change